Jun Eguchi Kazuya Miyashita Isamu Fukamachi Katsuyuki Nakajima Masami Murakami Yuko Kawahara Toru Yamashita Yasuyuki Ohta Koji Abe Atsuko Nakatsuka Mai Mino Satoru Takase Hiroaki Okazaki Robert A Hegele Michael Ploug Xuchen Hu Jun Wada Stephen G Young Anne P Beigneux
10.1016/j.jacl.2018.10.004
J Clin Lipidol
2019 Jan-Feb;13(1):62-69.
autoantibodies chylomicronemia gpihbp1 hypertriglyceridemia interferon β1a
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/30514621/
Autoimmune Diseases / immunology Drug-Related Side Effects and Adverse Reactions / immunology Hyperlipoproteinemia Type I / immunology Interferon-beta / adverse effects Multiple Sclerosis / therapy Receptors, Lipoprotein / immunology
Autoimmune Diseases / immunology Drug-Related Side Effects and Adverse Reactions / immunology Hyperlipoproteinemia Type I / immunology Interferon-beta / adverse effects Multiple Sclerosis / therapy Receptors, Lipoprotein / immunology Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Adult Autoantibodies / blood Autoimmune Diseases / etiology Cells, Cultured Female Humans Hyperlipoproteinemia Type I / etiology Interferon-beta / therapeutic use Multiple Sclerosis / complications Protein Binding Syndrome Triglycerides / blood Withholding Treatment Autoantibodies GPIHBP1 protein, human Receptors, Lipoprotein Triglycerides Interferon-beta
PMC6379125
30514621
GPIHBP1 autoantibody syndrome during interferon β1a treatment
2019